Novel sigma (σ) receptor agonists produce antidepressant-like effects in mice

European Neuropsychopharmacology

Volumn 17, Issue 11, 2007, Pages 708-716

  Wang, Jiajia ^a   Mack, Aisha L ^b   Coop, Andrew ^c   Matsumoto, Rae R ^a,b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Depression; ; Forced swim test; ; Mouse; Sigma receptor; ; UMB23; ; UMB82;

Indexed keywords

1 (3 PHENYLPROPYL)PIPERIDINE OXALATE; 1,2 DITOLYLGUANIDINE; 2 (3,4 DICHLOROPHENYL) N ETHYL N (2 PIPERIDIN 1 YLETHYL)ETHANAMINE OXALATE; ANTIDEPRESSANT AGENT; DESIPRAMINE; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; FLUVOXAMINE; GUANIDINE DERIVATIVE; N [2 (2,3 DICHLOROPHENYL)ETHYL] 2 DIMETHYLAMINO N METHYLETHYLAMINE; N [2 (3,4 DICHLOROPHENYL)ETHYL] N METHYL 2 (DIMETHYLAMINO)ETHYLAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NORADRENALIN TRANSPORTER; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE RECEPTOR; PIPERIDINE DERIVATIVE; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SIGMA 1 OPIATE RECEPTOR; SIGMA 2 OPIATE RECEPTOR; SIGMA OPIATE RECEPTOR; TRICYCLIC ANTIDEPRESSANT AGENT; UMB 23; UMB 82; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DEPRESSION; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; FORCED SWIMMING TEST; ISOTOPE LABELING; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RECEPTOR AFFINITY; TISSUE DISTRIBUTION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ETHYLENEDIAMINES; FREEZING REACTION, CATALEPTIC; MALE; MICE; MOTOR ACTIVITY; PIPERIDINES; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SIGMA; SWIMMING;

EID: 34548663639     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.02.007     Document Type: Article

References (58)

1. Aghajanian, G.K., 1978. Essays in neurochemistry and neuropharmacology. In: Youdim, M.B.H., Lovenberg, W., Sharman, D.F., Lagnado, J.R. (Eds.), John Wiley and Sons, New York, 3, 1-32.
2. Alonso G., Phan V., Guillemain I., Saunier M., Legrand A., Anoal M., and Maurice T. Immunocytochemical localization of the sigma-1 receptor in the adult rat central nervous system. Neuroscience 97 (2000) 155-170
3. Aydar E., Palmer C.P., Klyachko V.A., and Jackson M.B. The σ receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 34 (2002) 399-410
4. 1A receptors induced by venlafaxine. Neuropsychopharmacology 23 (2000) 294-306
5. Bermack J.E., and Debonnel G. Modulation of serotonergic neurotransmission by short- and long-term treatments with sigma ligands. Br. J. Pharmacol. 134 (2001) 691-699
6. Blier P., and de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15 (1994) 220-226
7. 3H] (+) pentazocine binding sites in the rat brain: Autoradiographic visualization of the putative sigma-1 and sigma-2 receptor subtypes. Neuroscience 76 (1997) 467-477
8. Chaput Y., de Montigny C., and Blier P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 333 (1986) 342-348
9. Costello E.J., Pine D.S., Hammen C., March J.S., Plotsky P.M., Weissman M.M., Biederman J., Goldsmith H.H., Kaufman J., Lewinsohn P.M., Hellander M., Hoagwood K., Koretz D.S., Nelson C.A., and Leckman J.F. Development and natural history of mood disorders. Biol. Psychiatry 52 (2002) 529-542
10. 2 Receptors regulate changes in sphingolipid levels in breast tumor cells. Eur. J. Pharmacol. 443 (2002) 207-209
11. Cryan J.F., and Mombereau C. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol. Psychiatry 9 (2004) 326-357
12. Cryan J.F., Markou A., and Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 23 (2002) 238-245
13. Daniels A., Ayala E., Pouw B., Coop A., and Matsumoto R.R. N-[2-(m-methoxyphenyl)ethyl]-N-ethyl-2-(1-pyrrolidinyl)ethylamine (UMB116) is a novel antagonist for cocaine-induced effects. Eur. J. Pharmacol. 542 (2006) 61-68
14. De Costa B.R., Radesca L., Di Paolo L., and Bowen W.D. Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines: structural requirements and binding affinity at the sigma receptor. J. Med. Chem. 35 (1992) 38-47
15. 2 Receptors are specially localized to lipid rafts in rat liver membranes. Eur. J. Pharmacol. 493 (2004) 19-28
16. 3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. J. Neurosci. 6 (1986) 1757-1770
17. 1-binding site. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 8072-8077
18. Itzhak Y., and Kassim C.O. Clorgyline displays high affinity for σ-binding sites in C57BL/6 mouse brain. Eur. J. Pharmacol. 176 (1990) 107-108
19. Iwamoto E.T. Locomotor activity and antinociception after putative mu, kappa and sigma opioid receptor agonists in the rat: influence of dopaminergic agonists and antagonists. J. Pharmacol. Exp. Ther. 217 (1981) 451-460
20. Jbilo O., Vidal H., Paul R., De Nys N., Bensaid M., Silve S., Carayon P., Davi D., Galiegue S., Bourrie B., Guillemot J.-C., Ferrara P., Loison G., Maffrand J.-P., Le Fur G., and Casellas P. Purification and characterization of the human SR 31747A-binding protein. A nuclear membrane protein related to yeast sterol isomerase. J. Biol. Chem. 272 (1997) 27107-27115
21. Jutkiewicz E.M. The antidepressant-like effects of delta-opioid receptor agonists. Mol. Interv. 6 (2006) 162-169
22. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., Wittchen H., and Kendler K.S. Lifetime and 12-month prevalence of DMS-III-R psychiatric disorders in the United States. Results from the National Cormorbidity Survey. Arch. Gen. Psychiatry 51 (1994) 8-19
23. 1 receptor agonist, in the rat brain. J. Pharmacol. Exp. Ther. 279 (1996) 106-113
24. Maeda D.Y., Williams W., Kin W.E., Thatcher L.N., Bowen W.D., and Coop A. N-Arylalkylpiperidines as high affinity sigma-1 and sigma-2 receptor ligands: phenylpropylamines as potential leads for sigma-2 agents. Bioorg. Med. Chem. Lett. 12 (2002) 497-500
25. Malberg J.E., and Blendy J.A. Antidepressant action: to the nucleus and beyond. Trends Pharmacol. Sci. 26 (2005) 631-638
26. Manji H.K., Quiroz J.A., Sporn J., Payan J.L., Denicoff K., Gray N.A., Zarate Jr. C.A., and Charney D.S. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol. Psychiatry 53 (2003) 707-742
27. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., and Gilbert P.E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197 (1976) 517-532
28. Matsumoto R.R., Bowen W.D., Tom M.A., Vo V.N., Truong D.D., and De Costa B.R. Characterization of two novel σ receptor ligands: antidystonic effects in rats suggest σ receptor antagonism. Eur. J. Pharmacol. 280 (1995) 301-310
29. Matsumoto R.R., Liu Y., Lerner M., Howard E.W., and Brackett D.J. σ Receptors: potential medications development target for anti-cocaine agents. Eur. J. Pharmacol. 469 (2003) 1-12
30. Matsumoto R.R., Gilmore D.L., Pouw B., Bowen W.D., Williams W., Kausar A., and Coop A. Novel analogs of the σ receptor ligand BD1008 attenuate cocaine-induced toxicity in mice. Eur. J. Pharmacol. 492 (2004) 21-26
31. 1 receptor agonist. Eur. J. Pharmacol. 306 (1996) 271-279
32. Mclean S., and Weber E. Autoradiographic visualization of haloperidol-sensitive sigma receptors in guinea-pig brain. Neuroscience 25 (1988) 259-269
33. 1 receptor. Biochem. Pharmacol. 62 (2001) 349-355
34. Narita N., Hashimoto K., Tomitaka S., and Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur. J. Pharmacol. 307 (1996) 117-119
35. Nestler E.J., and Carlezon Jr. W.A. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry 59 (2006) 1151-1159
36. Nestler E.J., Gould E., Manji H., Buncan M., Duman R.S., Greshenfeld H.K., Hen R., Koester S., Lederhendler I., Meaney M., Robbins T., Winsky L., and Zalcman S. Preclinical models: status of basic research in depression. Biol. Psychiatry 52 (2002) 503-528
37. Nicholson V.J., Wieringa J.H., and Van Delft A.M. Comparative pharmacology of mianserin, its main metabolites and 6-azamianserin. Naunyn-Schmiedeberg's Arch. Pharmacol. 319 (1982) 48-53
38. Okuyama S., Imagawa Y., Ogawa S., Araki H., Ajima A., Tanaka M., Muramatsu M., Nakazato A., Yamaguchi K., Yoshida M., and Otomo S. NE-100, a novel σ receptor ligand: in vivo tests. Life Sci. 53 (1993) PL285-PL290
39. Owens M.J. Molecular and cellular mechanisms of antidepressant drugs. Depress. Anxiety 4 (1996) 153-159
40. 1 receptor. J. Neurochem. 70 (1998) 2279-2285
41. Pharmaprojects, 2004. Igmesine hydrochloride, accession number 15962. PJB Pulications, Ltd.
42. Schechter L.E., Ring R.H., Beyer C.E., Hughes Z.A., Khawaja X., Malberg J.E., and Rosenzweig-Lipson S. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx. 2 (2005) 590-611
43. 3H]3-PPP binding to σ-sites in rat brain. Eur. J. Pharmacol. 165 (1989) 335-336
44. Seth P., Leibach F.H., and Ganapathy V. Cloning and structural analysis of the cDNA and the gene encoding the murine type 1 σ receptor. Biochem. Biophys. Res. Commun. 241 (1997) 535-540
45. Seth P., Fei Y.J., Li H.W., Huang W., Leibach F.H., and Ganapathy V. Cloning and functional characterization of a σ receptor from rat brain. J. Neurochem. 70 (1998) 922-931
46. Skuza G., and Rogoz Z. Effect of 1,3-di-o-tolylguanidine (DTG), rimcazole and EMD 57445, the σ receptor ligands, in the forced swimming test. Pol. J. Pharmacol. 49 (1997) 329-335
47. Skuza G., and Rogoz Z. A potential antidepressant activity of SA4503, a selective sigma receptor agonist. Behav. Pharmacol. 13 (2002) 537-543
48. Stahl S.M. Essential Psychopharmacology of Depression and Bipolar Disorder (2000), Cambridge University Press, New York
49. 3H]-SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. Eur. J. Pharmacol. 75 (1981) 81-82
50. 3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. J. Pharmacol. Exp. Ther. 223 (1982) 284-290
51. Takebayashi M., Hayashi T., and Su T.-P. Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: Implications for antidepressants. J. Pharmacol. Exp. Ther. 303 (2002) 1227-1237
52. Tardito D., Perez J., Tiraboschi E., Musazzi L., Racagni G., and Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol. Rev. 58 (2006) 115-134
53. Ukai M., Maeda H., Nanya Y., Kameyama T., and Matsuno K. Beneficial effects of acute and repeated administrations of σ receptor agonists on behavioral despair in mice exposed to tail suspension. Pharmacol. Biochem. Behav. 61 (1998) 247-252
54. 1-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J. Pharmacol. Exp. Ther. 298 (2001) 1269-1279
55. Vaupel D.B. Naltrexone fails to antagonize the sigma effects of PCP and SKF 10,047 in the dog. Eur. J. Pharmacol. 92 (1983) 269-274
56. 3H]tolyl)guanidine: a selective ligand that labels σ-type receptors for psychotomimetic opiates and antipsychotic drugs. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 8784-8788
57. Yagasaki Y., Numakawa T., Kumamaru E., Hayashi T., Su T.-P., and Kunugi H. Chronic antidepressants protentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. J. Biol. Chem. 281 (2006) 12941-12949
58. Young G.A., and Khazan N. Differential neuropharmacological effects of mu, kappa and sigma opioid agonists on cortical EEG power spectra in the rat. Stereospecificity and naloxone antagonism. Neuropharmacology 23 (1984) 1161-1165